Functions of NF-κB1 and NF-κB2 in immune cell biology

Biochemical Journal

Volumn 382, Issue 2, 2004, Pages 393-409

  Beinke, Sören ^a   Ley, Steven C ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

I B kinase (IKK); Nuclear factor B (NF B); p100; p105; Toll like receptor (TLR); Tumour progression locus 2 (TPL 2)

Indexed keywords

CYTOLOGY; GENES; IMMUNIZATION; POLYSACCHARIDES; PROTEINS;

LYMPHOCYTES; PROTEASOME;

CELL CULTURE;

CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 2; LIPOPOLYSACCHARIDE; LYMPHOTOXIN BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEASOME; PROTEIN P100; PROTEIN P105; PROTEIN P52; PROTEIN TPL 2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; TRANSCRIPTION FACTOR RELA;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; CELL KINETICS; DROSOPHILA; DRUG TARGETING; ENZYME RELEASE; GENE EXPRESSION; HODGKIN DISEASE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY DISEASE; KNOCKOUT MOUSE; LYMPHOCYTE FUNCTION; MACROPHAGE FUNCTION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; ANIMAL; HUMAN; IMMUNE SYSTEM; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNE SYSTEM; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; TRANSCRIPTION FACTOR RELA;

EID: 4544228457     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20040544     Document Type: Review

References (200)

1. Medzhitov, R. (2001) Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145
2. Takeda, K., Kaisho, T. and Akira, S. (2003) Toll-like receptors. Annu. Rev. Immunol. 21, 335-376
3. Zhang, G. and Ghosh, S. (2001) Toll-like receptor-mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunity. J. Clin. Invest. 107, 13-19
4. O'Neill, L. A. J. and Dinarello, C. A. (2000) The IL-1 receptor/Toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol. Today 21, 206-209
5. Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V. and Boldin, M. P. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331-367
6. Li, Q. and Verma, I. M. (2002) NF-κB regulation in the immune system. Nat Rev. Immunol. 2, 725-734
7. Weih, F. and Caamano, J. (2003) Regulation of secondary lymphoid organ development by the nuclear factor-κB signal transduction pathway. Immunol. Rev. 195, 91-105
8. Claudio, E., Brown, K., Park, S., Wang, H. and Siebenlist, U. (2002) BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat. Immunol. 3, 958-965
9. Girardin, S. E., Hugot, J.-P., and Sansonetti, P. J. (2003) Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 24, 652-658
10. Feldmann, M. and Maini, R. N. (2001) Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196
11. Karin, M. and Lin, A. (2002) NF-κB at the crossroads of life and death. Nat. Immunol. 3, 221-227
12. Karin, M., Cao, Y., Greten, F. R. and Zhi-Wei, L. (2002) NF-κB in cancer: from innocent bystander to major culprit, Nat. Rev. Cancer 2, 301-310
13. Farrow, B. and Evers, B. M. (2002) Inflammation and the development of pancreatic cancer. Surg. Oncol. 10, 153-169
14. Normark, S., Nilsson, C., Normark, B. H. and Hornef, M. W. (2003) Persistent infection with Helicobacter pylori and the development of gastric cancer. Adv. Cancer Res. 90, 63-89
15. Ghosh, S., May, M. J. and Kopp, E. B. (1998) NF-κB and Rel proteins: evolutionary conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260
16. Marienfeld, R., May, M. J., Berberich, I., Serfling, E., Ghosh, G. and Neumann, M. (2003) RelB forms transcriptionally inactive complexes with RelA/p65. J. Biol. Chem. 278, 19852-19860
17. Bours, V., Franzoso, G., Azarenko, V., Park, S., Kanno, T., Brown, K. and Siebenlist, U. (1993) The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 72, 729-739
18. Franzoso, G., Bours, V., Park, S., Tomita-Yamaguchi, M., Kelly, K. and Siebenlist, U. (1992) The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB mediated inhibition. Nature (London) 359, 339-342
19. Fujita, T., Nolan, G. P., Liou, H.-C., Scott, M. L. and Baltimore, D. (1993) The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through p50 homodimers. Genes Dev. 7, 1354-1363
20. Chen, L.-F. and Greene, W. C. (2004) Shaping the nuclear action of NF-κB. Nat. Immunol. Rev. 5, 392-401
21. Gerondakis, S., Morrice, N., Richardson, I. B., Wettenhall, R., Fecondo, J. and Grumont, R. J. (1993) The activity of a 70kDa IκB molecule identical to the carboxyl terminus of the p105 NF-κB precursor is modulated by protein kinase A. Cell Growth Differ. 4, 617-627
22. Inoue, J., Kerr, L. D., Kakizuka, A. and Verma, I. M. (1992) IκBγ, a 70 kDa protein identical to the C-terminal half of p100 NF-κB: a new member of the IκB family. Cell 68, 1109-1120
23. Pomerantz, J. L. and Baltimore, D. (2002) Two pathways to NF-κB. Mol. Cell 10, 693-701
24. Karin, M. and Ben-Neriah, Y. (2000) Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663
25. Yang, J., Lin, Y., Guo, Z., Cheng, J., Huang, J., Deng, L., Liao, W., Chen, Z., Liu, Z.-G. and Su, B. (2001) The essential role of MEKK3 in TNF-induced NF-κB activation. Nat. Immunol. 2, 620-624
26. Takaesu, G., Surabhi, R. M., Park, K.-J., Ninomiya-Tsuji, J., Matsumoto, K. and Gaynor, R. B. (2003) TAK1 is critical for IκB kinase-mediated activation of the NF-κB pathway. J. Mol. Biol. 326, 105-115
27. Liu, Y.-C. (2004) Ubiquitin ligases and the immune response. Annu. Rev. Immunol. 22, 81-127
28. Ben-Neriah, Y. (2002) Regulatory functions of ubiquitination in the immune system. Nat. Immunol. 3, 20-26
29. Silverman, N. and Maniatis, T. (2001) NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15, 2321-2342
30. Hoffmann, J. A. (2003) The immune response of Drosophila. Nature (London) 426, 33-38
31. Hultmark, D. (2003) Drosophila immunity: paths and patterns. Curr. Opin. Immunol. 15, 12-19
32. Morisato, D. and Anderson, K. V. (1995) Signaling pathways that establish the dorsal-ventral pattern of the Drosophila embryo. Annu. Rev. Genet. 29, 371-399
33. Silverman, N., Zhou, R., Stoven, S., Pandey, N., Hultmark, D. and Maniatis, T. (2000) A Drosophila IκB kinase complex required for Relish cleavage and antibacterial immunity. Genes Dev. 14, 2461-2471
34. Stoven, S., Ando, I., Kadalayil, L., Engstrom, Y. and Hultmark, D. (2000) Activation of the Drosophila NF-κB factor Relish by rapid endoproteolytic cleavage. EMBO Rep. 1, 347-352
35. Stoven, S., Silverman, N., Junell, A., Hedengren-Olcott, M., Erturk, D., Engstrom, Y., Maniatis, T. and Hultmark, D. (2003) Caspase-mediated processing of the Drosophila NF-κB factor Relish. Proc. Natl. Acad. Sci. U.S.A. 100, 5991-5996
36. Ishikawa, H., Carrasco, D., Claudio, E., Ryseck, R.-P. and Bravo, R. (1997) Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J. Exp. Med. 186, 999-1014
37. Scheinman, R. I., Beg, A. A. and Baldwin, A. S. (1993) NF-κB p100 (Lyt-10) is a component of H2TF1 and can function as an IκB-like molecule. Mol. Cell. Biol. 13, 6089-6101
38. Mercurio, F., DiDonato, J. A., Rosette, C. and Karin, M. (1993) p105 and p98 precursor proteins play an active role in NF-κB-mediated signal transduction. Genes Dev. 7, 705-718
39. Dobrzanski, P., Ryseck, R. P. and Bravo, R. (1995) Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 10, 1003-1007
40. Solan, N. J., Miyoshi, H., Bren, G. D. and Paya, C. V. (2001) RelB cellular regulation and transcriptional activity are regulated by p100. J. Biol. Chem. 277, 1405-1418
41. Yilmaz, Z. B., Weih, D., Sivakumar, V. and Weih, F. (2003) RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J. 22, 121-130
42. Caamano, J. H., Rizzo, C. A., Durham, S. K., Barton, D. S., Raventos-Suarez, C., Snapper, C. M. and Bravo, R. (1998) Nuclear Factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J. Exp. Med. 187, 185-196
43. Franzoso, G., Carlson, L., Poljak, L., Shores, E. W., Epstein, S., Leonardi, A., Grinberg, A., Tran, T., Scharton-Kersten, T., Anver, M. et al. (1998) Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J. Exp. Med. 187, 147-159
44. Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krahn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S.-C. and Karin, M. (2001) Activation by IKKα of a second evolutionary conserved, NF-κB signaling pathway. Science 293, 1495-1499
45. Yamada, T., Mitani, T. Yorila, K., Uchida, D., Matsushima, A., Iwamasa, K., Fujita, S. and Matsumoto, M. (2000) Abnormal immune function of hematopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-κB-inducing kinase. J. Immunol. 165, 804-812
46. Xiao, G., Harhaj, E. W. and Sun, S.-C. (2001) NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7, 401-409
47. Koike, R., Nishimura, T., Yasumizu, R., Tanaka, H., Hataba, Y., Watanabe, T., Miyawaki, S. and Miyasaka, M. (1996) The splenic marginal zone is absent in alymphoplastic aly mutant mice. Eur. J. Immunol. 26, 669-675
48. Yin, L., Wu, L., Wesche, H., Arthur, C. D., White, J. M., Goeddel, D. V. and Schreiber, R. D. (2001) Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science 291, 2162-2165
49. Miyawaki, S., Nakamura, Y., Suzuka, H., Koba, M., Ikehara, S. and Shibata, Y. (1994) A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur. J. Immunol. 24, 429-434
50. Kaisho, T., Takeda, K., Tsujimura, T., Kawai, T., Nomura, F., Terada, N. and Akira, S. (2001) IκB kinase α is essential for mature B cell development and function. J. Exp. Med. 193, 417-426
51. Regnier, C. H., Song, H. Y., Gao, X., Goeddel, D. V., Cao, Z. and Rothe, M. (1997) Identification and characterization of an IκB kinase. Cell 90, 373-383
52. Ling, L., Cao, Z. and Goeddel, D. V. (1998) NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. U.S.A. 95, 3792-3797
53. Xiao, G., Cvijic, M. E., Fong, A., Harhaj, E. W., Uhlik, M. T., Waterfield, M. and Sun, S.-C. (2001) Retroviral oncoprotein Tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα. EMBO J. 20, 6805-6815
54. Derudder, E., Dejardin, E., Pritchard, L. L., Green, D. R., Korner, M. and Baud, V. (2003) RelB/p50 dimers are differentially regulated by tumor necrosis factor-α and lymphotoxin-β receptor activation. J. Biol. Chem. 278, 23278-23284
55. Gommerman, J. L. and Browning, J. L. (2003) Lymphotoxin/LIGHT, lymphoid microenviroments and autoimmunedisease. Nat. Immunol. Rev. 3, 642-655
56. Muller, J. R. and Siebenlist, U. (2003) Lymphotoxin β receptor induces sequential activation of distinct NF-κB factors via separate signaling pathways. J. Biol. Chem. 278, 12006-12012
57. Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li, Z.-W., Karin, M., Ware, C. F. and Green, D. R. (2002) The lymphotoxin-β receptor induces different pathways of gene expression via two NF-κB pathways. Immunity 17, 525-535
58. Karrer, U., Althage, A., Odermatt, B., Hengartner, H. and Zinkernagel, R. M. (2000) Immunodeficiency of alymphoplasia mice (aly/aly) in vivo: structural defect in secondary lymphoid organs and functional B cell defect. Eur. J. Immunol. 30, 2799-2807
59. Ware, C. F., VanArsdale, T. L., Crowe, P. D. and Browning, J. L. (1995) The ligands and receptors of the lymphotoxin system. Curr. Top. Microbiol. Immunol. 198, 175-218
60. Kayagaki, N., Yan, M., Seshasayee, D., Wang, H., Lee, W., French, D. M., Grewal, I. S., Cochran, A. G., Gordon, N. C., Yin, J. et al. (2002) BAFF/BLys receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 10, 515-524
61. Coope, H. J., Atkinson, P. G. P., Huhse, B., Belich, M. P., Janzen, J., Holman, M., Klaus, G. G. B., Johnston, L. H. and Ley, S. C. (2002) CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J. 21, 5375-5385
62. Mackay, F., Schneider, P., Rennert, P. and Browning, J. (2003) BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231-264
63. Zarnegar, B., He, J. Q., Oganesyan, G., Hoffman, A., Baltimore, D. and Cheng, G. (2004) Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-κB activation pathways. Proc. Natl. Acad. Sci. U.S.A. 101, 8108-8113
64. Teitelbaum, S. L. (2000) Bone resorption by osteoclasts. Science 289, 1504-1508
65. Novack, D. V., Yin, L., Hagen-Stapleton, A., Schreiber, R. D., Goeddel, D. V., Ross, F. P. and Teitelbaum, S. L. (2003) The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198, 771-781
66. Saitoh, T., Nakayama, M., Nakano, H., Yagita, H., Yamamoto, N. and Yamaoka, S. (2003) TWEAK induces NF-κB2 p100 processing and long-lasting NF-κB activation. J. Biol. Chem. 278, 36005-36012
67. Saccani, S., Pantano, S. and Natoli, G. (2003) Modulation of NF-κB activity by exchange of dimers. Mol. Cell 11, 1563-1574
68. Mordmuller, B., Krappmann, D., Esen, M., Wegener, E. and Scheidereit, C. (2003) Lymphotoxin and lipopolysaccharide induce NF-κB p52 generation by a co-translational mechanism. EMBO Rep. 4, 82-87
69. Ekengren, S. and Hultmark, D. (1999) Drosophila cecropin as an antifungal agent. Insect Biochem. Mol. Biol. 29, 965-972
70. Malinin, N. L., Boldin, M. P., Kovalenko, A. V. and Wallach, D. (1997) MAP 3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature (London) 385, 540-544
71. Wajant, H., Henkler, F. and Scheurich, P. (2001) The TNF-receptor- associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell. Signalling 13, 389-400
72. Grammer, A. C. and Lipsky, P. E. (2001) CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv. Immunol. 76, 61-178
73. Saito, N., Courtois, G., Chiba, A., Yamamoto, N., Nitta, T., Hironaka, N., Rowe, M., Yamamoto, N. and Yamaoka, S. (2003) Two carboxy-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-κB through distinct signaling pathways in fibroblast cell lines. J. Biol. Chem. 278, 46565-46575
74. Tada, K., Okazaki, T., Sakon, S., Kobarai, T., Kurosawa, K., Yamaoka, S., Hashimoto, H., Mak, T. W., Yagita, H., Okumura, K. et al. (2001) Critical roles of TRAF2 and TRAF5 in TNF-induced NF-κB activaiton and protection from cell death. J. Biol. Chem. 276, 36530-36534
75. Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J.-I. and Chen, Z. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature (London) 412, 346-351
76. Sun, L. and Chen, Z. J. (2004) The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol. 16, 1-8
77. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D. and Courtois, G. (2003) The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature (London) 424, 801-805
78. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A. and Mosalios, G. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature (London) 424, 793-796
79. Liao, G., Zhang, M., Harhaj, E. W. and Sun, S.-C. (2004) Regulation of the NF-κB inducing kinase by TRAF3-induced degradation. J. Biol. Chem. 279, 26243-26250
80. Atkinson, P. G. P., Coope, H. J., Rowe, M. and Ley, S. C. (2004) Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-κB p100 to p52. J. Biol. Chem. 279, 51134-51142
81. Fong, A. and Sun, S.-C. (2002) Genetic evidence for the essential role of β-transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J. Biol. Chem. 277, 22111-22114
82. β-TrCP ubiquitin ligase. Oncogene 23, 2540-2547
83. Fong, A., Zhang, M., Neely, J. and Sun, S.-C. (2002) S9, a 19 S proteasome subunit interacting with ubiquitinated NF-κB2/p100. J. Biol. Chem. 277, 40697-40702
84. Heusch, M., Lin, L., Geleiunas, R. and Greene, W. C. (1999) The generation of nfkb2 p52: mechanism and efficiency. Oncogene 18, 6201-6208
85. Liao, G. and Sun, S.-C. (2003) Regulation of NF-κB2/p100 processing by its nuclear shuttling. Oncogene 22, 4868-4874
86. Rayet, B. and Gelinas, C. (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947
87. Ciana, P., Neri, A., Cappellini, C., Cavallo, F., Pomati, M., Chang, C.-C., Maiolo, A. T. and Lombardi, L. (1997) Constitutive expression of lymphoma-associated NF-κB/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene 14, 1805-1810
88. Chang, C.-C., Zhang, J., Lombardi, L., Neri, A. and Dalla-Favera, R. (1995) Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol. Cell. Biol. 15, 5180-5187
89. Kim, K.-E., Gu, C., Thakur, S., Vieira, E., Lin, J. C. and Rabson, A. B. (2000) Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes. Oncogene 19, 1334-1345
90. 1 transition. Mol. Cell. Biol. 21, 8428-8436
91. Viatour, P., Bentires-Alj, M., Chariot, A., Deregowski, V., de Leval, L., Merville, M.-P. and Bours, V. (2003) NF-κB2/p100 induces Bcl-2 expression. Leukemia 17, 1349-1356
92. Lanoix, J., Lacoste, J., Pepin, N., Rice, N. and Hiscott, J. (1994) Overproduction of NF-κB2 (lyt-10) and c-Rel: a mechanism for HTLV-1 Tax-mediated trans-activation via the NF-κB signaling pathway. Oncogene 9, 841-852
93. Ellopoulos, A. G., Caamano, J., Flavell, J., Reynolds, G. M., Murray, P. G., Poyet, J.-L. and Young, L. S. (2003) Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-κB2 to p52 via an IKKγ/NEMO-independent signalling pathway. Oncogene 22, 7557-7569
94. Luftig, M. A., Yasui, T., Soni, V., Kang, M.-S., Jacobson, N., Cahir-McFarland, E., Seed, B. and Kieff, E. (2004) Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKKα-dependent non-canonical NF-κB activation. Proc. Natl. Acad. Sci. U.S.A. 101, 141-146
95. Geleziunas, R., Ferrell, S., Lin, X., Mu, Y., Cunningham, E. T. J., Grant, M., Connelly, M. A., Hambor, J. E., Marcu, K. B. and Greene, W. C. (1998) Human T cell leukemia virus type I Tax induction of NF-κB involves activation of the IκB kinase α (IKKα) and IKKβ cellular kinases. Mol. Cell. Biol. 18, 5157-5165
96. Chu, Z.-L., DiDonato, J. A., Hawiger, J. and Ballard, D. W. (1998) The Tax oncoprotein of human T cell leukemia virus type I associates with and persistently activates IκB kinases containing IKKα and IKKβ. J. Biol. Chem. 273, 15891-15894
97. Hatzivassiliou, E. and Mosalios, G. (2002) Cellular signaling pathways engaged by the Epstein-Barr virus transforming protein LMP1. Front. Biosci. 7, 319-329
98. Wang, Y., Cui, H., Schroering, A., Ding, J. L., Lane, W. S., McGill, G., Fisher, D. E. and Ding, H.-F. (2002) NF-κB2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat. Cell Biol. 4, 888-893
99. Hacker, H. and Karin, M. (2002) Is NF-κB2/p100 a direct activator of programmed cell death? Cancer Cell 2, 431-433
100. Rice, N. R., MacKichan, M. L. and Israel, A. (1992) The precursor of NF-κB p50 has IκB-like functions. Cell 71, 243-253
101. Ishikawa, H., Claudio, E., Dambach, D., Raventos-Suarez, C., Ryan, C. and Bravo, R. (1998) Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p) 105 precursor (NF-κB1) but expressing p50. J. Exp. Med. 187, 985-996
102. Liou, H.-C., Nolan, G. P., Ghosh, S., Fujita, T. and Baltimore, D. (1992) The NF-κB p50 precursor, p105, contains an internal IκB-like inhibitor that preferentially inhibits p50. EMBO J. 11, 3003-3009
103. Ciechanover, A., Orian, A. and Schwartz, A. L. (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22, 442-451
104. Rape, M. and Jentsch, S. (2002) Taking a bite: proteasomal protein processing. Nat. Cell Biol. 4, 113-116
105. Lin, L. and Ghosh, S. (1996) A glycine-rich region in NF-κB p105 functions as a processing signal for the generation of the p50 subunit. Mol. Cell. Biol. 16, 2248-2254
106. Betts, J. C. and Nabel, G. J. (1996) Differential regulation of NF-κB2 (p100) processing and control by amino-terminal sequences. Mol. Cell. Biol. 16, 6363-6371
107. Orian, A., Schwartz, A. L., Israel, A., Whiteside, S., Kahana, C. and Ciechanover, A. (1999) Structural motifs involves in ubiquitin-mediated processing of the NF-κB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain. Mol. Cell. Biol. 19, 3664-3673
108. Levitskaya, J., Shapiro, A., Leonchiks, A., Ciechanover, A. and Masucci, M. G. (1997) Inhibition of ubiquitination/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U.S.A. 94, 12616-12621
109. Sharipo, A., Imreh, M., Leonchiks, A., Imreh, S. and Masucci, M. G. (1998) A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IκBα with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4, 939-944
110. Liu, C. W., Corboy, M. J., DeMartino, G. N. and Thomas, P. J. (2003) Endoproteolytic activity of the proteasome. Science 299, 408-411
111. Lee, C., Schwartz, M. P., Prakash, S., Iwakura, M. and Matouschek, A. (2001) ATP-dependent proteases degrade their substrates by processively unraveling them for the degradation signal. Mol. Cell 7, 627-637
112. Cohen, S., Orian, A. and Ciechanover, A. (2001) Processing of p105 is inhibited by docking of p50 active subunits to teh ankyrin repeat domain, and inhibition is alleviated by signaling via the carboxyl-terminal phosphorylation/ubiquitin-ligase binding domain. J. Biol. Chem. 276, 26769-26776
113. Harhaj, E. W., Maggirwar, S. B. and Sun, S. C. (1996) Inhibition of p105 processing by NF-κB proteins in transiently transfected cells. Oncogene 12, 2385-2392
114. Maier, H. J., Marienfeld, R., Wirth, T. and Baumann, B. (2003) Critical role of RelB serine 368 for dimerization and p100 stabilization. J. Biol. Chem. 278, 39242-39250
115. Lin, L., DeMartino, G. N. and Greene, W. C. (1998) Cotranslational biogenesis of NF-κB p50 by the 26 S proteasome. Cell 92, 819-828
116. Fan, C.-M. and Maniatis, T. (1991) Generation of p50 subunit of NF-κB by processing of p105 through an ATP-dependent pathway. Nature (London) 354, 395-398
117. Li, L., DeMartino, G. N. and Greene, W. C. (2000) Cotranslational dimerization of the Rel homology domain of NF-κB1 generates p50-p105 heterodimers and is required for effective p50 dimerization. EMBO J. 19, 4712-4722
118. Donald, R., Ballard, D. W. and Hawiger, J. (1995) Proteolytic processing of NF-κB/IκB in human monocytes. J. Biol. Chem. 270, 9-12
119. Belich, M. P., Salmeron, A., Johnston, L. H. and Ley, S. C. (1999) TPL-2 kinase regulates the proteolysis of the NF-κB inhibitory protein NF-κB1 p105. Nature (London) 397, 363-368
120. MacKichan, M. L., Logeal, F. and Israel, A. (1996) Phosphorylation of p105 PEST sequences via a redox-insensitive pathway up-regulates processing to p50 NF-κB. J. Biol. Chem. 271, 6084-6091
121. Mellits, K. H., Hay, R. T. and Goodbourn, S. (1993) Proteolytic degradation of MAD3 (IκBα) and enhanced processing of the NF-κB precursor p105 are obligatory steps in the activation of of NF-κB. Nucleic Acids Res. 21, 5059-5066
122. Salmeron, A., Janzen, J., Soneji, Y., Bump, N., Kamens, J., Allen, H. and Ley, S. C. (2001) Direct phosphorylation of NF-κB p105 by the IκB kinase complex on serine 927 is essential for signal-induced p105 proteolysis. J. Biol. Chem. 276, 22215-22222
123. Lang, V., Janzen, J., Fischer, G. Z., Soneji, Y., Beinke, S., Salmeron, A., Allen, H., Hay, R. T., Ben-Neriah, Y. and Ley, S. C. (2003) βTrCP-mediated proteolysis of NF-κB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol. Cell. Biol. 23, 402-413
124. βTrCP-mediated ubiquitination and degradation for the NF-κB precursor p105 and IκBα. Mol. Cell. Biol. 21, 1024-1035
125. Beinke, S., Belich, M. P. and Ley, S. C. (2002) The death domain of NF-κB1 p105 is essential for signal-induced p105 proteolysis. J. Biol. Chem. 277, 24162-24168
126. Heissmeyer, V., Krappmann, D., Wulczyn, F. G. and Scheidereit, C. (1999) NF-κB p105 is a target on IkB kinases and controls signal induction of BCL-3-p50 complexes. EMBO J. 18, 4766-4788
127. βTrCP ubiquitin ligase-mediated processing of NF-κB p105 requires phosphorylation of its C-terminus by IκB kinase. EMBO J. 19, 2580-2591
128. Syrovets, T., Jendrach, M., Rohwedder, A., Schule, A. and Simmet, T. (2001) Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKK-β-mediated NF-κB activation. Blood 97, 3941-3950
129. Ten, R. M., Paya, C. V., Israel, N., Le Bail, O., Mattei, M. G., Virelizier, J. L., Kourilsky, P. and Israel, A. (1992) The characterization of the promoter of the gene encoding the p50 subunit of NF-κB indicates that it participates in its own regulation. EMBO. J. 11, 195-203
130. βTrCP- independent processing. Mol. Cell. Biol. 24, 475-486
131. βTrCP1 ubiquitin ligase. Genes Dev. 11, 1445-1456
132. Demarchi, F., Berloli, C., Sandy, P. and Schneider, C. (2003) Glycogen synthase-3β regulates NF-κB1/p105 stability. J. Biol. Chem. 278, 39583-39590
133. Demarchi, F., Verardo, R., Varnum, B., Brancolini, C. and Schneider, C. (2001) Gas6 anti-apoptotic signaling requires NF-κB activation. J. Biol. Chem. 276, 31738-31744
134. Takeda, K. and Akira, S. (2004) TLR signaling pathways. Semin. Immunol. 16, 3-9
135. Patriotis, C., Makris, A., Bear, S. E. and Tsichlis, P. N. (1993) Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T cell lymphomas and in T cell activation Proc. Natl. Acad. Sci. U.S.A. 90, 2251-2255
136. Miyoshi, J., Higashi, T., Mukai, H., Ohuchi, T. and Kakunaga, T. (1991) Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol. Cell. Biol. 11, 4088-4096
137. Salmeron, A., Ahmad, T. B., Carlile, G. W., Pappin, D., Narsimnan, R. P. and Ley, S. C. (1996) Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 15, 817-826
138. Dumitru, C. D., Ceci, J. D., Tsatsanis, C., Kontoyiannis, D., Stamatakis, K., Lin, J.-H., Patriotis, C., Jenkins, N. A., Copeland, N. G., Kollias, G. and Tsichlis, P. N. (2000) TNFα induction by LPS is regulated post-transcriptionally via a TPL2/ERK-dependent pathway. Cell 103, 1071-1083
139. Eliopoulos, A. G., Dumitru, C. D., Wang, C.-C., Cho, J. and Tsichlis, P. N. (2002) Induction of COX-2 by LPS in macrophages is regulated by TPL2-dependent CREB activation signals. EMBO J. 21, 4831-4840
140. Eliopoulos, A. G., Wang, C.-C., Dumitru, C. D. and Tsichlis, P. N. (2003) TPL-2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 22, 3855-3864
141. Beinke, S., Deka, J., Lang, V., Belich, M. P., Walker, P. A., Howell, S., Smerdon, S. J., Gamblin, S. J. and Ley, S. C. (2003) NF-κB p105 negatively regulates TPL-2 MEK kinase activity. Mol. Cell. Biol. 23, 4739-4752
142. Lang, V., Symons, A., Watton, S. J., Janzen, J., Soneji, Y., Beinke, S., Howell, S. and Ley, S. C. (2004) ABIN2 forms a ternary complex with TPL-2 and NF-κB1 p105 and is essential for TPL-2 protein stability. Mol. Cell. Biol. 24, 5235-5248
143. Waterfield, M. R., Zhang, M., Norman, L. P. and Sun, S.-C. (2003) NF-κB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the TPL-2 kinase. Mol. Cell 11, 685-694
144. Ceci, J. D., Patriotis, C. P., Tsatsanis, C., Makris, A. M., Kovatch, R., Swing, D. A., Jenkins, N. A., Tsichlis, P. N. and Copeland, N. G. (1997) TPL-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev. 11, 688-700
145. Swantek, J. L., Christerson, L. and Cobb, M. H. (1999) Lipopolysaccaride-induced tumor necrosis factor-α promoter activity is inhibitor of nuclear factor-κB kinase dependent. J. Biol. Chem. 274, 11667-11671
146. Chen, C.-C., Sun, Y.-T., Chen, J.-J. and Chang, Y.-J. (2001) Tumor necrosis factor-α-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IκB kinase 1/2 in human alveolar epithelial cells. Mol. Pharmacol. 59, 493-500
147. Caivano, M., Gorgoni, B., Cohen, P. and Poli, V. (2001) The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein β (C/EBP β) and C/EBPδ transcript. J. Biol. Chem. 276, 48693-48701
148. Park, J. M., Brady, H., Ruocco, M. G., Sun, H., Williams, D., Lee, S. J., Kato, T., Richards, N., Chan, K., Mercurio, F. et al. (2004) Targeting of TAK1 by the NF-κB protein Relish regulates the JNK-mediated immune response in Drosophila. Genes Dev. 18, 584-594
149. Varfolomeev, E. E. and Ashkenazi, A. (2004) Tumor necrosis factor: an apoptosis JuNKie? Cell 116, 491-497
150. Ferrier, R., Nougarede, R., Doucet, S., Kahn-Perles, B., Imbert, J. and Mathieu-Mahul, D. (1999) Physical interaction of the bHLH LYL1 protein and NF-κB1 p105. Oncogene 18, 995-1005
151. Baer, R. (1993) TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin. Cancer Biol. 4, 341-347
152. Li, Z., Zhang, J., Chen, D. and Shu, H.-B. (2003) Casper/c-FLIP is physically and functionally associated with NF-κB1 p105. Biochem. Biophys. Res. Commun. 309, 980-985
153. Krueger, A., Baumann, S., Krammer, P. H. and Kirchhoff, S. (2001) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21, 8247-8254
154. Bouwmeester, T., Bauch, A., Ruffner, H., Angrand, P.-O., Bergamini, G., Croughton, K., Crucial, C., Eberhard, D., Gagneur, J. and Ghidelli, S. (2004) A physical and functional map of the human TNFα/NF-κB signal transduction pathway. Nat. Cell Biol. 6, 97-105
155. van Huffel, S., Delaei, F., Heyninck, K., de Valck, D. and Beyaert, R. (2001) Identification of a novel A20-binding inhibitor of nuclear factor-κB activation termed ABIN-2. J. Biol. Chem. 276, 30216-30223
156. Beyaert, R., Heyninck, K. and van Huffel, S. (2000) A20 and A20-binding proteins as cellular inhibitors of nuclear factor-κB-dependent gene expression and apoptosis. Biochem. Pharmacol. 60, 1143-1151
157. Lee, E. G., Boone, D. L., Chai, S., Libby, S. L., Chien, M., Lodolce, J. P. and Ma, A. (2000) Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350-2354
158. Sha, W. C., Liou, H.-C., Tuomanen, E. I. and Baltimore, D. (1995) Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80, 321-330
159. Grumont, R. J., Rourke, I. J., O'Reilly, L. A., Strasser, A., Miyake, K., Sha, W. and Gerondakis, S. (1998) B lymphocytes differentially use the Rel and nuclear factor κB1 (NF-κB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J. Exp. Med. 187, 663-674
160. Sha, W. C., Lious, H.-C., Tuomanen, E. I. and Baltimore, D. (1995) Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80, 321-330
161. Snapper, C., Zelazowski, P., Rosas, F. R., Kehry, M. R., Tian, M., Baltimore, D. and Sha, W. C. (1996) B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J. Immunol. 156, 183-191
162. Zheng, Y., Ouaaz, F., Bruzzo, P., Singh, V., Gerondakis, S. and Beg, A. A. (2001) NF-κB RelA (p65) is essential for TNF-α-induced Fas expression but dispensable for both TCR-induced expression and activation-induced cell death. J. Immunol. 166, 4949-4957
163. + Th1 cell development and resistance to Leishmania major. J. Immunol. 170, 1995-2003
164. Artis, D., Shapira, S., Mason, N., Speirs, K. M., Goldschmidt, M., Caamano, J., Liou, H. C., Hunter, C. A. and Scott, P. (2002) Differential requirement for NF-κB family members in control of helminth infection and intestinal inflammation. J. Immunol. 169, 4481-4487
165. Das, J., Chen, C. H., Yang, L., Cohn, L., Ray, P. and Ray, A. (2001) A critical role for NF-κB in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2, 45-50
166. Kanters, E., Gijbels, M. J., van der Made, I., Vergouwe, M. N., Heeringa, P., Kraal, G., Hofker, M. H. and de Winther, M. P. (2004) Hematopoietic NF-κB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood 103, 934-940
167. Bohuslav, J., Kravchenko, V. V., Parry, G. C. N., Erlich, J. H., Gerondakis, S., Mackman, N. and Ulevitch, R. J. (1998) Regulation of an essential innate immune response by the p50 subunit of NF-κB. J. Clin. Invest. 102, 1645-1652
168. Lamhamedi-Cherradi, S.-E., Zheng, S., Hilliard, B. A., Xu, L., Sun, J., Alsheadat, S., Liou, H.-C. and Chen, Y. H. (2003) Transcriptional regulation of type I diabetes by NF-κB. J. Immunol. 171, 4886-4892
169. Campbell, I. K., Gerondakis, S., O'Donnell, K. and Wicks, I. P. (2000) Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. 105, 1799-1806
170. Yang, L., Cohn, L., Zhang, D. H., Homer, R., Ray, A. and Ray, P. (1998) Essential role of nuclear factor κB in the induction of eosinophilia in allergic airway inflammation. J. Exp. Med. 188, 1739-1750
171. Erdman, S. E., Fox, J. G., Dangler, C. A., Feldman, D. and Horwitz, B. H. (2001) Typhlocolitis in NF-κB-deficient mice. J. Immunol. 166, 1443-1447
172. Karban, A. S., Okazaki, T., Panhuysen, C. I., Gallegos, T., Potter, J. J., Bailey-Wilson, J. E., Silverberg, M. S., Duerr, R. H., Cho, J. H., Gregersen, P. K. et al. (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet. 13, 35-45
173. Ishikawa, H., Ryseck, R. P. and Bravo, R. (1996) Charaterization of ES cells deficient for the p105 precursor (NF-κB1): role of p50 NLS. Oncogene 13, 255-263
174. Liptay, S., Schmid, R. M., Perkins, N. D., Meltzer, P., Altherr, M. R., McPherson, J. D., Walsmuth, J. J. and Nabel, G. J. (1992) Related subunits of NF-κB map to two distinct loci associated with translations in leukemia, NF-κB1 and NF-κB2. Genomics 13, 287-292
175. Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M.-P. and Castronovo, V. (1994) The NF-κB transcription factor and cancer: high expression of NF-κB. Biochem. Pharmacol. 47, 145-149
176. Mukhopadhyay, T., Roth, J. A. and Maxwell, S. A. (1995) Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 11, 999-1003
177. Michaux, L., Mecucci, C., Stul, M., Wlodarska, I., Hernandez, J. M., Meeus, P., Michaux, J. L., Scheiff, M. M., Noel, H., Louwagie, A. et al. (1996) BCL3 rearrangement and t(14;19) (q32;q13) in lymphoproliferative disorders. Genes Chromosomes Cancer 15, 38-47
178. Lenardo, M. and Siebenlist, U. (1994) Bcl-3-mediated nuclear regulation of the NF-κB transactivating factor. Immunol. Today 15, 145-147
179. Ong, S. T., Hackbarth, M. L., Degenstein, L. C., Baunoch, D. A., Anastasi, J. and McKeitnan, T. W. (1998) Lymphadenopathy, splenomegaly and altered immunoglobulin production in BCL-3 transgenic mice. Oncogene 16, 2333-2343
180. Thornburg, N. J., Pathmanathan, R. and Raab-Traub, N. (2003) Activation of nuclear factor-κB p50 homodimer/BCL-3 complexes in nasopharyngeal carcinoma. Cancer Res. 63, 8293-8301
181. Sun, S.-C. and Ballard, D. W. (1999) Persistent activation of NF-κB by the Tax transforming protein of HTLV-1: hijacking cellular IκB kinases. Oncogene 18, 6948-6958
182. Watanabe, M., Muramatsu, M. A., Hirai, H., Suzuki, T., Fujisawa, J., Yoshida, M., Arai, K. I. and Arai, N. (1993) HTLV-1 encoded Tax in association with NF-κB precursor p105 enhances nuclear localization of NF-κB p50 and p65 in transfected cells. Oncogene 8, 2949-2958
183. Hirai, H., Fujisawa, J., Suzuki, T., Ueda, K., Muramatsu, M., Tsuboi, A., Arai, N. and Yoshida, M. (1992) Transcriptional activator Tax of HTLV-1 binds to the NF-κB precursor p105. Oncogene 7, 1737-1742
184. Munoz, E., Courtois, G., Veschambre, P., Jalinot, P. and Israel, A. (1994) Tax induces nuclear translocation of NF-κB through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of IκBα/MADS. J. Virol. 68, 8035-8044
185. Rousset, R., Desbois, C., Bantignies, F. and Jalinot, P. (1996) Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome. Nature (London) 381, 328-331
186. Karin, M., Yamamoto, Y. and Wang, Q. M. (2004) The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17-26
187. Sun, S.-C. and Xiao, G. (2003) Deregulation of NF-κB and its upstream kinases in cancer. Cancer Metastasis Rev. 22, 405-422
188. Kontoyiannis, D., Boulougouris, G., Manoloukos, M., Armaka, M., Apostolaki, M., Pizarro, T. T., Kotlyarov, A., Forster, I., Flavell, R. A., Gaestel, M. et al. (2002) Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J. Exp. Med. 196, 1563-1574
189. Locksley, R. M., Killeen, N. and Lenardo, M. J. (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501
190. Marshall, C. J. (1994) MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Gene. Dev 4, 82-89
191. Caamano, J., Tato, C., Cai, G., Villegas, E. N., Speirs, K., Craig, L., Alexander, J. and Hunter, C. A. (2000) Identification of a role for NF-κB2 in the regulation of apoptosis and in maintainance of T cell-mediated immunity to Toxoplasma gondii. J. Immunol. 165, 5720-5728
192. Weih, F., Warr, G., Yang, H. and Bravo, R. (1997) Multifocal defects in immune responses in RelB-deficient mice. J. Immunol. 158, 5211-5218
193. Weih, D. S., Yilmaz, Z. B. and Weih, F. (2001) Essential role of RelB in germinal center and marginal zone formation and proper expression of homing chemokines. J. Immunol. 167, 1909-1919
194. Weih, F., Carrasco, D., Durham, S. K., Barton, D. S., Rizzo, C. A., Ryseck, R.-P., Lira, S. A. and Bravo, R. (1995) Multiorgan inflammation and hematopoietic abnormalities in mice with targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 80, 331-340
195. Snapper, C. M., Rosas, F. R., Zelazowski, P., Moorman, M. A., Kehry, M. R., Bravo, R. and Weih, F. (1996) B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation to Ig secretion and Ig class switching. J. Exp. Med. 184, 1537-1541
196. Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L. A., Olson, D., Tizard, R., Cate, R. and Lo, D. (1995) Expression of relB is required for the development of thymic medulla and dendritic cells. Nature (London) 373, 531-536
197. Paxian, S., Merkle, H., Riemann, M., Wilda, M., Adler, G., Hameister, H., Liptay, S., Pfeffer, K. and Schmid, R. M. (2002) Abnormal organogenesis of Peyer's patches in mice deficient for NF-κB1, NF-κB2, and Bcl-3. Gastroenterology 122, 1853-1868
198. Schwarz, E. M., Krimpenfort, P., Berns, A. and Verma, I. M. (1997) Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 11, 187-197
199. Matsumoto, M., Yamada, T., Yoshinaga, S. K., Boone, T., Horan, T., Fujita, S., Li, Y. and Mitani, T. (2002) Essential role of NF-κB-inducing kinase in T cell activation through the TCR/CD3 pathway. J. Immunol. 169, 1151-1158
200. Futterer, A., Mink, K., Luz, A., Kosco-Vilbois, M. H. and Pfeffer, K. (1998) The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissue. Immunity 9, 59-70